Article

Does Medical Activism Actually Work?

This question entered my mind when I read the compelling story, "Moms, Regulators, Biotech Startups, and the Battle Over a Potentially Life-Saving Drug."

This question entered my mind when I read the compelling story, “Moms, Regulators, Biotech Startups, and the Battle Over a Potentially Life-Saving Drug,” in Bloomberg BusinessWeek. Although the article doesn’t provide an answer, it seems to hint that it does.

The focus of the feature is Duchenne muscular dystrophy, a rare genetic disease that primarily affects boys. It describes the struggle of several affected families who are seeking care for their sons, as well as the role of FDA and the efforts of biotech companies to get a drug into the market.

As you read through the story, it is easy to identify with the parents’ struggle. At times, you may feel thankful that it is not your story, but want to help in the family’s struggles. You also get insight into the role social media can play in how “scientific” decisions are influenced.

Why did the FDA seem to reverse course on eteplirsen but allow Sarepta Therapeutics to move ahead in seeking regulatory approval? What do you think?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit: Sebastian Kaulitzki | stock.adobe.com
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com